Invitation to submit Phase II contract, Sigmovir Biosystems 75N93024C00040
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health (NIH) is forecasting a new requirement to invite Sigmovir Biosystems to submit a Phase II contract proposal, with an estimated solicitation release date of November 1, 2026 and an estimated award date of July 1, 2027. The Phase II effort expands the work from Sigmovir's Phase I contract, which successfully generated and validated reagents for unique immune models, to producing additional reagents for biomedical research on health and disease. The requirement is set aside for total small business.
The estimated award value range is $1.5 million to $3 million under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). Points of contact are Callie Prassinos, Contracting Officer at NIH (callie.prassinos@nih.gov, +12406695155), and Stacy Ferguson at the National Institute of Allergy and Infectious Diseases (fergusonst@niaid.nih.gov).
Forecast text
This PCAIS entry is to request that Sigmovir Biosystems be invited to submit a Phase II contract proposal. This contractor provided significant benefit to the government in their prior Phase I contract by successfully generating and validating reagents needed for unique immune models. The Phase II invitation will be an expansion of these activities including generation of more unique reagents needed in the biomedical field for studying health and diseases.
Statement of impact: If this PCAIS entry is not approved, this will reduce the ability of the government to invest in the generation of reagents that are needed to conduct research using unique immune models that are important for studying health and disease, by not allowing a contractor with the capacity to generate the reagents the opportunity to submit a contract proposal for consideration.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast